F. Aber

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

K. Dooley, P. Denti, D. Sloan, 2020, Trials.

“It is not easy”: Experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda

R. King, M. Kesby, D. Sloan, 2023, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.

Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.

K. Dooley, P. Denti, D. Sloan, 2022, Clinical Infectious Diseases.